Syngene International Ltd (SYNGENE)
₹406.65
Mkt cap
₹16,415 Cr
P/E ratio
45.60
P/B
3.48
Div yield
0.31%
ROE
7.71%
ROCE
9.91%
EPS (TTM)
₹8.92
Book value
₹117
52W range
390–722
Sector
Healthcare
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−43.68% from high₹407
₹390+4.30% from low₹722
Current
₹406.65
Prev close
₹406.50
Day
+0.04%
Price performance
1D
+0.04%
1W
−2.62%
1M
−6.84%
3M
−3.45%
6M
−32.90%
1Y
−39.34%
YTD
−38.24%
Financials
FRevenue, profit & margin
P/E ratio
45.6×
SYNGENE is 18% above the sector median of 38.6×
SYNGENE45.6×
Sector median38.6×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 994 | 808 | 910 | 854 | 917 | 790 | 891 | 944 | 1,018 | 874 | 911 | 917 | 1,036 | |
| Expenses | 680 | 596 | 656 | 622 | 600 | 620 | 646 | 660 | 674 | 668 | 711 | 708 | 733 | |
| Operating Profit | 314 | 212 | 254 | 232 | 317 | 170 | 245 | 284 | 344 | 206 | 200 | 209 | 303 | |
| OPM % | 32% | 26% | 28% | 27% | 35% | 22% | 27% | 30% | 34% | 24% | 22% | 23% | 29% | |
| Other Income | 23 | 24 | 14 | 26 | 16 | 50 | 16 | 18 | 19 | 18 | 15 | -55 | 16 | |
| Interest | 10 | 10 | 13 | 11 | 13 | 12 | 13 | 12 | 16 | 12 | 13 | 12 | 12 | |
| Depreciation | 96 | 102 | 105 | 108 | 111 | 107 | 111 | 109 | 106 | 111 | 116 | 114 | 112 | |
| Profit before tax | 231 | 123 | 151 | 138 | 209 | 101 | 137 | 181 | 240 | 101 | 85 | 28 | 196 | |
| Tax % | 23% | 24% | 23% | 19% | 10% | 25% | 23% | 27% | 24% | 14% | 21% | 47% | 25% | |
| Net Profit | 179 | 93 | 116 | 112 | 189 | 76 | 106 | 131 | 183 | 87 | 67 | 15 | 148 | |
| EPS in Rs | 4.45 | 2.32 | 2.90 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 4.55 | 2.15 | 1.67 | 0.37 | 3.67 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
29 Jul '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.61% · closed higher next day 19 of last 40
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 26 Jul '23◦ | 18 Oct '23◦ | 26 Jan '24◦ | 25 Apr '24◦ | 25 Jul '24 | 23 Oct '24◦ | 23 Jan '25◦ | 24 Apr '25 | 23 Jul '25 | 5 Nov '25◦ | 22 Jan '26◦ | 29 Apr '26◦ |
| Earnings day | +5.87% | −1.95% | −0.30% | −0.07% | +5.50% | +5.13% | −6.01% | −12.78% | +0.70% | −4.01% | −8.23% | +8.21% |
| +1 day | +8.21% | −2.48% | +4.60% | −0.27% | +4.97% | +4.54% | −9.63% | −15.89% | −0.92% | −4.68% | −17.36% | +10.46% |
| +5 days | +4.76% | −6.18% | +8.20% | −3.67% | +11.10% | +2.80% | −11.85% | −16.18% | +6.81% | +2.41% | −21.07% | +6.00% |
| +15 days | +5.38% | −1.48% | +11.37% | −1.21% | +11.42% | +0.71% | −17.08% | −13.85% | −2.49% | −1.01% | −26.59% | +6.87% |
| +30 days | +10.13% | +0.84% | +1.23% | +1.60% | +20.64% | +5.28% | −19.76% | −13.76% | −4.08% | +1.63% | −30.93% | +4.94% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 1.25 Per Share | 1.25 | 25 Jun '26 | 26 Jun '26 |
Shareholding
Sas of Jun 202652.59%Promoter
Promoters52.59%0.09
FIIs11.82%2.09
DIIs28.01%1.57
Public7.15%0.46
Ownership trend
Peers
P7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹406.65 | 45.55 | 16,415 | 0.31% | 148 | −11.82% | 960 | +1.22% | 9.91% |
| Indegene | ₹492.65 | 28.63 | 11,869 | 0.46% | 80 | −19.14% | 1,003 | +32.80% | 18.82% |
| Suven Life Scie. | ₹316.00 | — | 8,929 | 0.00% | −46 | −3.78% | 2 | +3.40% | −76.92% |
| Vimta Labs | ₹570.45 | 31.55 | 2,549 | 0.35% | 21 | +11.38% | 109 | +11.80% | 25.23% |
| Fabtech Tech. | ₹149.73 | 13.69 | 666 | 0.00% | 4 | +154.79% | 75 | +10.25% | 13.58% |
| Take Solutions | ₹20.79 | 72.19 | 308 | 0.00% | 4 | +1,353.33% | 54 | — | 18.51% |
| Novelix Pharma. | ₹69.99 | 77.84 | 199 | 0.00% | 1 | +405.56% | 25 | +20.76% | 9.98% |
| Median: 9 Co. | ₹149.73 | 38.55 | 666 | 0.00% | 4 | +154.79% | 75 | +11.03% | 9.98% |
Filings
DAnnual reports12
Concall transcripts81
TranscriptApr 2026PPTApr 2026RECApr 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTSep 2025TranscriptJul 2025PPTJul 2025TranscriptApr 2025RECApr 2025PPTMar 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptOct 2024PPTOct 2024TranscriptJul 2024PPTJul 2024RECJul 2024TranscriptApr 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2d - Syngene will hold Q1 FY2027 results conference call on 30 July 2026 at 9:00 AM IST.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 2dAnnouncement under Regulation 30 (LODR)-Change in Management 14 Jul - General Counsel Surender Sharma to leave Syngene by mutual consent on July 15, 2026.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Jul - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ending June 30, 2026. 8 Jul - Board meeting on July 29, 2026 to approve Q1 FY27 results; analyst call on July 30.